

+ PTO/SB/05 (08-00) Please type a sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Attorney Docket No. PT049P1 UTILITY Ebner et al. First Inventor PATENT APPLICATION Serine/ThreoninePhosphatase Polynucleotides, **TRANSMITTAL** Polypeptides, and Antibodies (Only for new nonprovisional applications under 37 CFR & 1.53(b)) Express Mail Label No. Assistant Commissioner for Patents APPLICATION ELEMENTS Box Patent Application ADDRESS TO: See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 1. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer (Submit an original, and a duplicate for fee processing) Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission Applicant claims small entity status. 2. (if applicable, all necessary) See 37 CFR 1.27. a. Computer Readable Form (CRF) b. Specification Sequence Listing on: 3. 🖂 [Total Pages 329] Specification i. CD-ROM or CD-R (2 copies); or (preferred arrangement set forth below) - Descriptive title of the Invention - Cross Reference to Related Applications ii. 🛛 paper (28 pages) c. Statements verifying identity of above copies Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, ACCOMPANYING APPLICATION PARTS or a computer program listing appendix+ - Background of the Invention - Brief Summary of the Invention Assignment Papers (cover sheet and document(s)) - Brief Description of the Drawings (if filed) - Detailed Description Power of Attorney 10. 37 CFR 3.73(b) Statement Claim(s) - Abstract of the Disclosure 11. English Translation Document (if applicable) 4. Drawing(s) (35 U.S.C. 113) [Total Sheets 5. 🛛 Unexecuted Oath or Declaration 12. Information Disclosure Statement/ Form PTO/SB/08 a. Newly executed (original or copy) Copies of Citations b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) 13. Preliminary Amendment i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 88 1.63(d)(2) and 1.33(b). 14. Return Receipt Postcard (MPEP 503) (should be specifically itemized) Application Data Sheet. See 37 CFR 1.76. 15. Certified copy of Priority Document(s) (if foreign priority is claimed) 16. Other: 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: of prior application No: PCT/US01/06256 Divisional Continuation-in-Part (CIP) Prior application information Examiner Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application. from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been madvertently omitted from the submitted application parts. 18. CORRESPONDENCE ADDRESS or Correspondence address below 22195 Customer Number or Bar Code Label NAME ADDRESS CITY STATE ZIP CODE COUNTRY TELEPHONE FAX NAME (Print/Type) 40,302 Registration No. (Attorney/Agent) Kenley K. Hoover SIGNATURE August 30, 2001

r Statement: this form is estimated to the 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete ould be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: promissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (U9-UU)

Approved for use through 10/31/2002 OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001								Complete if Known						
Patent fees are subject to annual revision.														
i mem jees are subject to unimal revision.								Application Number Unassig					ed	
							Filing Date					August 30, 2001		
							First Named Inventor					Ebner et al.		
							Examiner Name							
								Group Art Unit						
Total amount of payment (\$)746.00								y Docke	Number	r	PT049P	1		
METHOD OF PAYMENT (CHECK ONE)										FEI	E CALCULATION (CO	NTINUED)		
1. The Commissioner is hereby authorized to charge indicated								DDITION						
fees and credit any overpayment to: Deposit Account 08-3425								ntity Fee	Small En Fee	tity Fee	Fee		Fee Paid	
Number								(\$)	Code	(\$)	Description			
		int Human	Genon	ne Scienc	es, Inc.		105	130	205	65	Surcharge - late provisio	nal filing fee or cover		
Name								50	227	25	sheet Surcharge - late provision	nal filing fee or cover		
								20	22.	20	sheet	ALL THANK TO UT OF THE		
Charge Any Additional Fee Required								130	139	130	Non-English specification			
Under 37 CFR §§ 1.16 and 1.17							147 112	2,520	147	2,520		a request for ex parte reexamination		
Financia . pres								920	112	920	Requesting publication of action	ng publication of SIR prior to Examiner		
Applicant claims small entity status See 37 CFR 1.27								1,840	113	1,840	Requesting publication of action	of SIR after Examiner		
See 37 CFR 1.27								110	215	55	Extension for reply with	in first month		
								390	216	195	Extension for reply with	ın second month		
2 Payment Enclosed:								890	217	445	Extension for reply with	1		
☐ Check ☐ Credit Card ☐ Money Order ☑ Other								1,390	218	695	Extension for reply with	1		
Echarge any deficiencies or credit any overpayments in the fees or fee adculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425								1,890	228	945	Extension for reply with	in 11th month		
The state of the s								310	219	155	Notice of Appeal			
FEE CALCULATION								310	220	155	Filing a brief in support	of an appeal		
1 BASIC FILING FEE								270	221	135	Request for oral hearing			
Large Fee	Entity	Small	Entity	Fee		Fee	138	1,510	138	1,510	Petition to institute a pul	blic use proceeding		
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Description	l .	Paid						ļ		
<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	710	201	355	Utility filing	g fee	\$710.00	140	110	240	55	Petition to revive -unavo	oidable		
106	320	206	160	Design filin	g fee		141	1,240	241	620	Petition to revive - unint	entional		
107	490	207	245	Plant filing			142	1,240	242	620	Utility issue fee (or ress	sue)		
108 114	710 150	208 214	355 75	Reissue fili			143 144	440 600	243 244	220 300	Design issue fee Plant issue fee			
214 150 214 75 Provisional filing fee						122	130	122	130	Petitions to the Commiss	sioner			
Subtotal (1) \$710.00								50	123	50	Petitions related to provi	isional applications		
								240	126	240	Submission of Informati	1		
2. EXTRA CLAIM FEES							581	40	481	40	Recording each patent as (times number of proper		l	
				į	Fee	Fee	146	710	246	355	Filing a submission after			
				Extra	from	Paid					(37 CFR 1.129(a))	-		
Total clai	ms	22	- 20**	2	below	\$36.00	149	710	249	355	For each additional inve CFR 1 129(b))	ntion to be examined (37		
Indep.claims 2 - 3** 0 \$0.00				179	710	279	355	Request for Continued E	Examination (RCE)					
Multiple	•			T		S	169	190	169	900	Request for expedited ex	xammation of a design		
Depender	at .		 	+		 	Other for	e (specify)			application			
Large	Entity	Small	Entity	Fee	<u></u>	1	3	e (specify):	•					
Fee	Fee	Fee	Fee	Description	on		- LIIO1 100	. (opoury):						
Code	(S)	Code	(S)	l			***	11 . 5 .	mu:	D				
103 18 203 9 Claims in excess of 20							*Reduced by Basic Filing Fee Paid							
102							ł							
104					(}			
108	108 80 209 40 **Reissue independent claims over original patent													
over original patent 110 18 210 9 **Reissue claims in excess of 20						Subtotal (3) \$						\$		
and over original patent						<u> </u>								
							ł						L	
			i				I						ì	
Subtot	al (2)		(9	3)746.00			l						į	
Submi	tted D-	T					 						omplete (if applicable)	
			Han	vor 1			Degist	Registration No.: 40,302 Telephone					301-309-8504	
Name (Print/Type) Keprley K. Hoover / Registrat										JUZ		Date Aug		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ebner et al.

Application Serial No.: Not assigned Art Unit: Not assigned

Filed: Concurrently herewith Examiner: Not assigned

For: Serine/Threonine Phosphatase Polynucleotides,

Polypeptides, and Antibodies Attorney Docket No.: PT049P1

STATEMENT UNDER 37 C.F.R. 1.821(f)

Assistant Commissioner for Patents Washington, D.C. 20231

Date: Gugust 30, 2001

Sir:

Applicants hereby certify that the hard copy of the sequence listing being filed concurrently herewith and the enclosed computer-readable form of such sequence listing are identical.

Respectfully submitted,

Kenley K. Hoover

Reg. No. 40,302

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, Maryland 20850 Telephone: (301) 610-5771

KKH/JS/ur